3Bar Biologics

Investors · 1

RE

Rev1 VenturesreportedColumbusvia David Bergeron · board

$2.4M disclosed across 2 rounds · 2016–2020

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

TH

Third Arc Bio10 shared keywordsThird Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering. The company is led by a team with a track record of 35+ drug approvals.

3T

3T Biosciences10 shared keywords3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.

AG

Agfundernews8 shared keywordsAgFunderNews is a news publication covering agrifood technology, including alternative protein, agtech, and foodtech companies and industry developments.

TR

TripleBar Bio, Inc.7 shared keywordsTriplebar builds an AI platform for Genomic Design Automation (GDA), using microfluidics to generate large-scale biological datasets with matched genotype and phenotype at lower cost and faster than liquid handling robotics. It applies machine learning to biological data to support biotechnology research and product engineering.

3P

3PBIOVIAN5 shared keywords3PBIOVIAN is a contract development and manufacturing organization (CDMO) providing biologics development and manufacturing services—including process development, analytical testing, GMP clinical production, and commercial-scale manufacturing—for protein expression systems and viral vectors. It serves biotech and pharmaceutical companies across Europe, the US, and Asia, operating manufacturing sites in Spain and Finland.

32

32 Biosciences Website5 shared keywords32 Biosciences develops gut mucosal-immune science to prevent and treat gastrointestinal diseases, offering a GI discovery platform that measures metabolomic signatures of the gut mucosal-immune system and a therapeutic platform based on a Mucosal Immune Modulator (MIM) that restores and protects the gastrointestinal mucosal-immune barrier. Its lead therapeutic asset is CS-0003.

Companies competing with 3Bar Biologics for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.